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Groups A and B, respectively (P = 0.483). The adverse 
effects in the two groups were essentially the same.
Conclusions Biomarker-tailored chemotherapy based on 
ERCC1, RRM1, and β-tubulin III expression showed sig-
nificantly increased response rate, median PFS time, and 
1-year survival rate in patients with NSCLC.
Keywords Chemotherapy · Non-small cell lung cancer · 
Molecular biomarkers · Efficacy
Introduction
Lung cancer is one of the leading causes of cancer-related 
mortality for both men and women worldwide [1]. Non-
small cell lung cancer (NSCLC) accounts for approxi-
mately 75–80 % of all lung cancer cases. Nearly two-thirds 
of NSCLC patients have unresectable advanced diseases 
upon diagnosis. Combined modality treatment has become 
the standard of care for cancer therapy in the past few 
years, and chemotherapy is an integral part of the treatment 
for lung cancer [2]. For the patients with advanced NSCLC, 
chemotherapy prolongs survival and improves quality of 
life and platinum-based chemotherapy has been accepted 
as a standard therapy [3]. However, for those patients, the 
2-year overall survival (OS) rate remains <15 %. Despite 
tremendous efforts devoted to develop monotherapy or 
combinational chemotherapy regimens, therapeutic out-
comes are still poor [4].
Recently, it has been increasingly suggested that tai-
lored individual chemotherapy based on molecular bio-
markers represents a novel avenue for NSCLC treatment 
[5, 6]. Indeed, biomarker-based molecularly targeted 
therapy has made an unprecedented progress in the treat-
ment for NSCLC in the past decade. A good example is the 
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application of epidermal growth factor receptor (EGFR) 
inhibitors to a subset of patients bearing certain mutations, 
which results in a favorable response [5]. Likewise, exci-
sion repair cross-complementing gene 1 (ERCC1), ribo-
nucleotide reductase M1 (RRM1), and β-tubulin III sta-
tuses have been reported to correlate with the therapeutic 
efficacy of platinum, gemcitabine, and docetaxel, respec-
tively [6–9]. While biomarker-guided chemotherapy shows 
potentials in benefiting patients, most evidences came 
from retrospective studies and are often limited to a single 
molecular signature [10–12]. It has been increasingly rec-
ognized that a single molecule may not be able to precisely 
predict the patient’s response, and a cluster of molecular 
biomarkers would be more appropriate to guide clinical 
decision-making.
Platinum, gemcitabine, and docetaxel represent the 
most important chemotherapeutic agents used in the treat-
ment of advanced NSCLC [2]. Recently, a growing num-
ber of studies aimed to identify molecular signatures that 
can predict the clinical outcomes of these agents. Among 
the suggested biomarkers, ERCC1 is well-studied. ERCC1 
is a critical component of nucleotide excision repair, a pri-
mary DNA repair mechanism that removes platinum–DNA 
adducts from genomic DNA [7]. It has been reported that 
ERCC1-negative tumors have a better response to adjuvant 
cisplatin-based chemotherapy [8], whereas high expres-
sion of ERCC1 results in drug resistance [9]. Both retro-
spective [10] and prospective [11] studies aiming to assess 
the predictive utility of ERCC1 status for platinum-based 
chemotherapy in NSCLC have revealed improved clini-
cal outcomes by integrating patient’s ERCC1 status in 
developing individualized therapy [12, 13]. In terms of 
gemcitabine-based therapy, RRM1, which catalyzes a rate-
limiting step in the production of deoxyribonucleotides 
required for DNA synthesis, has been strongly suggested as 
a candidate biomarker [14]. An increased level of RRM1 
enables cancer cells to more efficiently repair DNA damage 
caused by chemotherapy, resulting in resistance to gemcit-
abine. In fact, RRM1 is believed to be the predominant cel-
lular determinant of the efficacy of the nucleoside analogue 
gemcitabine [15]. For instance, a meta-analysis of Gong 
et al. [16] has shown that RRM1-low or RRM1-negative 
advanced NSCLC is associated with a higher response rate 
to gemcitabine-containing regimen and a better prognosis. 
Taxanes exert their anti-tumor effects by binding to and 
stabilizing intracellular microtubules [17]. Recent studies 
have revealed that the expression of β-tubulin III is associ-
ated with the tumor sensitivity to docetaxel treatment [18]. 
Patients with lower levels of β-tubulin III are more sensi-
tive to docetaxel treatment [19, 20], while β-tubulin III 
high expression represents an independent risk factor for 
the poor progression-free survival (PFS) of cancer patients 
receiving such treatment [21]. Collectively, these findings 
demonstrate that the β-tubulin III mRNA level can be used 
as an independent predictive biomarker for the outcome of 
the paclitaxel-/vinorelbine-based chemotherapy [22].
In the present study, we attempted to integrate ERCC1, 
RRM1, and β-tubulin III expression levels into the deci-
sion-making of chemotherapy for NSCLC. It was hoped 
that this prospective, feasibility study would help assess 
the therapeutic values of the molecular biomarker-guided 
chemotherapy for the treatment of advanced NSCLC.
Patients and methods
Patients
A total of 85 advanced NSCLC patients admitted at our 
hospital (Zhongda Hospital Affiliated to Southeast Univer-
sity, Nanjing, People’s Republic of China) between Janu-
ary 2007 and August 2011 were recruited into this study. 
The following inclusion criteria were used: (1) pathologi-
cal- and radiological-based diagnosis of stage IIIB or IV, 
inoperable NSCLC; (2) measurable tumors using comput-
erized tomography (CT) scanning; (3) Eastern Coopera-
tive Oncology Group (ECOG) performance status between 
0 and 2; (4) predicted survival time ≥3 months; and (5) 
signed informed consent to participate in the study.
Patients were excluded if any of the following crite-
ria was met: (1) ECOG performance status >2; (2) severe 
complications, including cardiovascular and pulmonary 
diseases, bone marrow suppression, liver and renal dys-
functions, and/or organ failures; (3) brain metastasis; 
(4) chemotherapy history; (5) predicted survival time 
<3 months; and (6) unwillingness to receive chemotherapy.
Clinical trial design
The trial was designed to prospectively assess the thera-
peutic values of intratumoral molecular analysis in guiding 
chemotherapy options for patients with advanced NSCLC. 
Patients with sufficient tumor tissue amounts obtained by 
either fiberoptic bronchoscopy or CT-guided needle biopsy 
for molecular probing were assigned into Group A, and 
the rest of patients were assigned into Group B as con-
trols. Intratumoral expression levels of ERCC1, RRM1, 
and β-tubulin III were examined by immunohistochem-
istry (IHC) analysis, which was used for determining the 
chemotherapy regimens for each patient. Therapy regimens 
for patients in Group B were based on the National Com-
prehensive Cancer Network Clinical Practice Guidelines 
for NSCLC. They were planned to be treated with stand-
ard first-line gemcitabine–cisplatin regimens for 4–6 cycles 
(21 days per cycle). In case of disease progression or severe 
adverse effects, regimens were adjusted: Patients received 
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follow-up treatment using single-agent or second-line treat-
ment until death or the end of the study.
The study protocol was reviewed and approved by the 
Ethical Committee of Zhongda Hospital Affiliated to 
Southeast University, Nanjing, People’s Republic of China. 
As aforementioned, each of the patients signed an informed 
consent before entry into the study.
Specimen collection and analysis
Tumor specimens from patients were initially obtained by 
using fiberoptic bronchoscopy. However, for tumors located 
beyond the coverage of fiberoptic bronchoscopy, mostly 
in peripheral pulmonary areas, CT-guided needle biopsy 
was applied. Tissues were fixed in 10 % neutral-buffered 
formalin, embedded in paraffin wax, and then sectioned 
to 2-µm-thick slides for the analysis for ERCC1, RRM1, 
or β-tubulin III expression using IHC with the PO-7000 
commercial kit (ZSGB-Bio, Beijing, People’s Republic of 
China) following the manufacturer’s instructions. Primary 
antibodies were as follows: mouse anti-ERCC1 antibody 
(Cat# 12A00409; ZSGB-Bio, Beijing, People’s Repub-
lic of China), rabbit anti-RRM1 antibody (Cat# 60073-
1-lg; BJGB-Bio, Beijing, People’s Republic of China), 
and mouse anti-III β-tubulin antibody (Cat#1226P1011B; 
BJGB-Bio, Beijing, People’s Republic of China).
Semiquantitative analysis of the IHC staining was 
performed independently by two experienced patholo-
gists. The intensity of the staining was graded by the fol-
lowing scale: 0 = no staining, + = weak staining, and 
++ = strong staining. Staining in human fetal cells, which 
were primary cells derived from human specimen and vali-
dated pathologically in our hospital (++) as well as human 
tonsil cells (++), and human brain cells (++), was used 
as positive controls for scoring the ERCC1, RRM1, and 
β-tubulin III staining, respectively.
Chemotherapy regimens
Patients in Group A received different chemotherapy regi-
mens according to their ERCC1, RRM1, and β-tubulin 
III expression statuses. Patients with ERCC1-negative or 
ERCC1-low were given platinum-based doublets (cisplatin 
or carboplatin in combination with docetaxel, paclitaxel, 
vinorelbine, gemcitabine, or pemetrexed); RRM1-negative 
or RRM1-low received either gemcitabine single-agent 
or gemcitabine-based doublets; and patients with high 
β-tubulin III expression avoided taxanes. As pemetrexed is 
not recommended for treatment of squamous carcinoma, 
those patients with high expression of RRM1 and β-tubulin 
III were not included in this study. Based on these prin-
ciples, patients in Group A were divided into seven sub-
groups receiving various regimens (Table 1). All patients 
in Group B were treated with gemcitabine plus cisplatin in 
every 21-day cycle. 
Patients in both groups were given routine anti-vomit-
ing medications prior to chemotherapy. For those receiv-
ing regimens containing cisplatin, adequate hydration was 
given. During the treatment, routine blood tests and liver 
and renal functions were monitored.
Efficacy assessment
Prior to chemotherapy, all patients provided their treat-
ment history and underwent a series of medical examina-
tions, including pathological examination, CT scan of chest 
(upper abdomen and adrenal glands), emission CT bone 
scan, brain CT, or magnetic resonance imaging, complete 
blood cell counts, platelet counts, and biochemical analysis 
for liver and renal functions. All tests were repeated every 
two cycles of treatment. Tumor response was assessed 
according to the RECIST 1.1 criteria [23] and categorized 
as complete response (CR), partial response (PR), sta-
ble disease (SD), and progressive disease (PD). Response 
rate (%) was defined by following formula: (CR + PR)/all 
treated patients × 100 %. Disease control rate (DCR) (%) 
was defined by following formula: (CR + PR + SD)/all 
treated patients × 100 %.
Survival analyses were performed on an intent-to-treat 
basis. OS was calculated from the date of assignment to 
either the date of death or last clinical follow-up, whichever 
occurred first. PFS was the time interval between the dates 
of first treatment and either disease progression or death, 
whichever occurred first. Adverse effects caused by chemo-
therapy were scored by 0–IV degrees based on the WHO 
standard.
Statistical analysis
Patients’ characteristics were described as median (inter-
quartile range—IQR = 25–75 %) or frequencies (%). Con-
tinuous variables were compared using the Kruskal–Wallis 
test. Categorical variables were compared using the χ2 test. 
Kaplan–Meier survival curves were compared by using the 
log-rank test. P values <0.05 were considered statistically 
significant. Data were analyzed using the SPSS v17.0 sta-
tistical software package (SPSS, Inc., Chicago, IL, USA).
Results
Patients’ characteristics
From January 2007 to August 2011, 85 patients were 
registered into the trial. Biopsy was obtained from each 
patient. Among them, 31 had CT-guided lung biopsies, 
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50 had bronchoscopy-guided lung biopsies, and 4 had 
biopsies from organs other than lung. All patients com-
pleted the study, and 41 of them, whose biopsies were 
suitable for IHC, were subjected to measurements of 
ERCC1, RRM1, and β-tubulin III. Patients’ character-
istics in both groups were compared, and there were no 
significant difference in patients number, gender, age, 
or ECOG performance status scores (P > 0.05; Table 2) 
(Fig. 1).
Efficacy
We firstly compared the response rates of patients in both 
groups. Among those in Group A, treatment responses were 
as follows: CR in none patient, PR in 23 patients = 56.1 % 
(95 % CI 39.1–70.7 %), SD in 13 patients = 31.7 % (95 % 
CI 17.1–46.3 %), and PD in five patients = 12.2 % (95 % 
CI 2.4–22.0 %). The overall response rate (CR + PR) was 
56.1 %. In contrast, for patients in Group B, the responses 
included CR in none patient, PR in 14 patients = 31.8 % 
(95 % CI 18.2–45.5 %), SD in 20 patients = 45.5 % (95 % 
CI 29.5–61.3 %), and PD in ten patients = 11.4 % (95 % 
CI 2.3–20.5 %). The overall response rate in Group B was 
31.8 %, significantly lower than that in Group A (P = 0.024).
We next compared survivals of patients in both groups. 
PFS and OS curves are shown in Fig. 2. Median PFS 
times were 5.2 months (IQR = 2.85–5.90 months) for 
Group A versus 4.1 months (IQR = 2.85–4.82 months) 
for Group B, showing significant differences between the 
two groups (P = 0.026). It was also noticed that 1-year 
survival rate in Group A was higher than that in Group B 
(65.9 vs. 40.9 %, respectively; P = 0.021). However, the 
median survival times of both groups were very simi-
lar (13.5 months—IQR = 8.97–15.57 months) for Group 
A versus 12.5 months (IQR = 7.72–17.34 months) for 
Group B; P = 0.483). There was no difference in DCR rate 
between the two groups 87.8 versus 77.3 % (P = 0.203) 
(Table 3).
Adverse effects
At the time of assessment, patients in Group A had received 
4.05 cycles of treatment whereas those in Group B had 
received 4.23 cycles. Bone marrow suppression, gastroin-
testinal reactions, and liver and renal dysfunctions repre-
sented the most common adverse effects caused by chem-
otherapy. We next compared the adverse effects resulting 
Table 1  Treatment regimens for patients in Group A
Therapy regimen: gemcitabine: 1,000 mg/m2 , days 1 and 8; cisplatin: 75 mg/m2 within 3 days; paclitaxel: 135 mg/m2, day 1; carboplatin: area 
under the time–concentration curve = 6, day 1; docetaxel: 75 mg/m2, day 1; pemetrexed: 500 mg/m2, day 1
− = Low expression; + = High expression
Biomarkers RRM1− β-Tubulin III− β-Tubulin III+
ERCC− Gemcitabine + cisplatin – –
ERCC − plus RRM1+ – Paclitaxel + carboplatin/docetaxel + cisplatin Pemetrexed + cisplatin
ERCC + plus RRM1− – Gemcitabine + paclitaxel Gemcitabine
ERCC + plus RRM1+ – Paclitaxel + docetaxel Pemetrexed
Table 2  Patients’ characteristics
Group A: inter-quartile range 25–75 % of age between 56 and 70.5; 
Group B: inter-quartile range 25–75 % of age between 53.25 and 70
Total Group A Group B P
Patients’ number (%) 85 41 (48.2) 44 (51.8) –
Gender
 Male (%) 54 25 (46.3) 29 (53.7) 0.637
 Female (%) 31 16 (51.6) 15 (48.4)
Age
 Range 29–85 29–78 34–85 –
 Medians 65 64 62
 ECOG performance status 
0/1/2
– 11/24/6 9/26/9 0.679
Pathological types
 Squamous cell carcinoma  
(%)
36 17 (47.2) 19 (52.8) 0.873
 Adenocarcinoma (%) 49 24 (49.0) 25 (51.0)
Stages
 IIIB (%) 37 19 (51.4) 18 (48.6) 0.614
 IV (%) 48 22 (45.8) 26 (54.2)
Chemotherapy regimens
 Gemcitabine +cisplatin (%) – 19 (46.3) 44 (100.0) –
 Paclitaxel + carboplatin (%) – 6 (14.6) –
 Docetaxel + cisplatin (%) – 6 (14.6) –
 Pemetrexed + cisplatin (%) – 5 (12.2) –
 Gemcitabine (%) – 3 (7.3) –
 Paclitaxel (%) – 2 (4.9) –
 Gemcitabine + paclitaxel  
(%)
– 0 (0.0) –
 Pemetrexed (%) – 0 (0.0) –
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from chemotherapy in the two groups (Table 4). Toxicities 
greater than grade III were very similar in the two groups 
(P = 0.431 for bone marrow suppression; P = 0.911 for 
nausea and vomiting; P = 0.564 for liver and renal dys-
functions). Moreover, methods for toxicity management, 
such as anti-vomiting medications, were effective in both 
groups.
Discussion
Currently, therapy with platinum-based doublets is the 
standard care for first-line treatment of patients with 
advanced NSCLC and has achieved a good performance 
status (0–1) [3]. However, the selection of chemotherapeu-
tic agents is generally based on convenience, side effect 
profiles, and the physician’s experience. The individual-
ized chemotherapy is lagging far behind molecularly tar-
geted therapy, which has validated molecular signatures in 
NSCLC and clearly defined target patient populations. In 
spite of the increasing number of clinical studies to explore 
therapeutic opportunities of individualized chemotherapy 
based on a large number of patients, such as BATTLE trial 
[24], it remains unclear how to tailor regimens for individ-
ual patient to further improve the therapeutic efficacy.
We have noticed that an increasing number of molecules 
have been suggested to correlate with the chemo-sensitiv-
ity in clinical studies. These candidate biomarkers mostly 
Fig. 1  A workflow chart showing a molecular signature tailored 
chemotherapy trial for the treatment for NSCLC. Flowchart and treat-
ment algorithm used for selection of tailored chemotherapy based on 
molecular signature. Patients with ERCC1-negative or ERCC1-low 
were given platinum-based doublets; RRM1-negative or RRM1-low 
received either gemcitabine single agent or gemcitabine-based dou-
blets; and patients with high β-tubulin III expression avoided taxanes
Fig. 2  Comparison of therapeutic efficacy. a OS curves. b PFS esti-
mates by treatment arm. Blue line Group A chemotherapy regimens 
were determined according to the patient’s molecular signatures; 
green line Group B treatment with gemcitabine plus cisplatin regi-
men. The differences in median OS were not statistically significant 
(log-rank test P = 0.483). The median PFS time of Group A is sig-
nificantly longer than Group B (log-rank test P = 0.026)
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stem from the growing understanding of molecular action 
mechanisms for these agents. It is conceivable that strati-
fying the patients based on these molecular signatures will 
improve the effectiveness of chemotherapy and/or reduce 
side effects. However, prospective studies in this regard are 
rare, and, among the limited studies, findings are often in 
discrepancy. Our prospective study aimed to assess the pre-
dictive utility of ERCC1, RRM1, and β-tubulin III expres-
sion in chemotherapy of NSCLC. By simultaneously inte-
grating the expression status of three candidate biomarkers 
into the regimen selection, we compared the response 
rates, PFS, OS, and toxicities between patients treated with 
biomarker-guided therapy and those treated with standard 
gemcitabine/cisplatin regimen, a widely used combination 
in any stage of NSCLC and with advantages in improving 
the OS or PFS compared to other platinum-based regimens, 
suggested by a meta-analysis [25]. We observed the signifi-
cantly improved response rate, PFS time, and 1-year sur-
vival rate, but no change in the OS rate or DCT. However, 
we noticed that a recent prospective study by Bepler et al. 
[26] did not observe a survival or response rate from indi-
vidualized therapy using ERCC1 and RRM1 expression as 
molecular signatures. We speculate that the difference may, 
at least partially, stem from the different approaches used 
for measuring expression of molecular signatures. In their 
study, Bepler et al. [26] used RT-PCR instead of IHC to 
measure the intratumoral expression of ERCC1 and RRM1, 
which may not ensure the detection of functional proteins. 
Also, it was a multicenter study, and criteria between the 
centers might vary. The authors have claimed that their 
finding is false negative and believed that protein expres-
sion analysis for therapeutic decision-making is feasible 
in newly diagnosed patients with advanced-stage NSCLC 
[26].
In the present study, we also compared the adverse 
effects after chemotherapy in the two groups. Common 
adverse effects, like bone marrow suppression and gas-
trointestinal reactions, were observed in both groups and 
most were grade I or II toxicities. There was no statistic 
difference between the two groups, suggesting that chance 
of increased adverse effects resulted from individualized 
chemotherapy is relatively small, further strengthening its 
clinical potential.
Meanwhile, it is important to mention that our study 
has its limitations in patients grouping. It is a feasibility 
study rather than a randomized study. Although we did not 
observe significant differences in patient number, gender, 
age, or ECOG performance status scores between the two 
groups, a randomized control trial is needed to verify our 
results in the future.
The integration of molecular biomarkers into the clinical 
decision-making largely relies on the molecular profiling in 
cancer tissues. Lately, multiple approaches are being devel-
oped [8]. Currently, IHC analysis [10], RT-PCR [21], and 
quantitative analysis of in situ protein [27] have been per-
formed in retrospective studies. However, it still requires 
more studies to conclude on an appropriate approach for 
clinical applications [28]. IHC provides information on 
the protein expression level and its localization, which has 
become the standard in situ assay to assess protein expres-
sion. IHC may prove to be the most attractive option based 
on the relative uniform results, few limitations, and a broad 
clinical applicability. However, IHC is semiquantitative, 
subjective, and may be affected by a range of poorly con-
trolled variables. For example, Friboulet et al. [29] have 
reported that IHC analysis with the use of currently avail-
able ERCC1 antibodies does not specifically detect the 
unique functional ERCC1 isoform, which may limit the 
utility of ERCC1 in predicting the patients’ responsiveness 
to therapy. Instead, they reached their conclusion based on 
the analysis of isolated cells. Likewise, Toffart et al. [30] 
have analyzed up to eight molecules, such as ERCC1, 
Table 3  Therapeutic efficacy assessment
CR Complete response, PR partial response, SD stable disease, PD 
progressive disease, ND not determined, OR overall response rate, 
DCT disease control rates





CR 0 0 – –
PR 23 14 – –
SD 13 20 – –
PD 5 10 – –
ND 0 0 – –
OR (%) 56.1 31.8 5.09 0.024
DCR (%) 87.8 77.3 1.62 0.203
Median survival time (month) 13.5 12.5 0.513 0.483
Median PFS time (month) 5.2 4.1 5.498 0.026
Table 4  Adverse effect 
assessment
* χ2 = 1.683, P = 0.431
#
 Fisher’s exact, P = 0.911
†
 Fisher’s exact, P = 0.564
Group A Group B
0 I + II III + IV 0 I + II III + IV
Bone marrow suppression (%)* 13 (31.7) 25 (61.0) 3 (7.3) 11 (25.0) 26 (59.1) 7 (15.9)
Nausea plus vomiting (%)# 15 (36.6) 25 (61.0) 1 (2.4) 18 (40.9) 25 (56.8) 1 (2.3)
Liver and renal dysfunctions (%)† 33 (80.5) 7 (17.1) 1 (2.4) 31 (70.5) 10 (22.7) 3 (6.8)
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BRCA1, and TUBB3, in small size of non-surgical biop-
sies using IHC and failed to reveal the associated therapeu-
tic efficacy in terms of DCR, PFS, or OS. We included the 
biomarkers into regimen assignments, which may account 
for the different conclusions between our studies and Tof-
fart et al.’s [30] study. As indicated by these authors, also 
the small size of non-surgical biopsies often left no slides 
for IHC studies. That is indeed the reason which restricted 
us from a randomized design and instead subgrouping the 
patients according to the feasibility of the IHC.
In oncology clinic, quality assessment tools for examin-
ing prognostic and predictive biomarkers are still lacking. 
For prospective studies, the ability to carry out molecular 
detection with a small amount of tissues, like biopsies, is 
essential. Attempts to detect gene expression in broncho-
scopic or fine needle aspiration biopsies have emerged 
lately and not yet been applied broadly. Encouragingly, sev-
eral recent studies have suggested that the limited amount 
of bronchoscopic or fine needle aspiration biopsies would 
allow establishing gene profiling and molecular tumor clas-
sification and might become a powerful adjunct for the 
daily clinical practice [31, 32]. Recently, Suwinski et al. 
[33] have successfully integrated multiple molecular sig-
natures from bronchoscopic biopsies into predicting clini-
cal outcomes. In agreement with these findings, our study 
has shown that biopsies from 41 of the 85 patients included 
were eligible for IHC-based gene expression detection, but 
its potential for a broad application needs to be examined in 
future studies.
In conclusion, our prospective study applied IHC to 
measure ERCC1, RRM1, and β-tubulin III expression in 
biopsies, and assessed the potential benefits of the three 
molecular biomarker-guided chemotherapy and the adverse 
effects in the treatment for NSCLC. Our results have dem-
onstrated that tailored chemotherapy based on ERCC1, 
RRM1, and β-tubulin III expression showed significantly 
increased response rate, median PFS time, and 1-year sur-
vival rate in patients with NSCLC, without an increase in 
adverse effects.
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